Transplantation in Special Populations

Transplantation in Special Populations

Transplantation in Special Populations

On this page

Transplantation in Special Populations - Tiny Titans, Big Hopes

  • Pediatric transplantation: unique challenges in growth, neurodevelopment, adherence, psychosocial aspects.
  • Anatomical: smaller vessels, organ size mismatch, technical modifications.
  • Immunosuppression: weight/BSA-based dosing; ↑risk PTLD (EBV-driven), infections. Monitor long-term effects.
  • Common indications:
    • Liver: Biliary atresia (most common).
    • Kidney: CAKUT (Congenital Anomalies of the Kidney and Urinary Tract).
    • Heart: Congenital heart defects.
  • Growth & development: critical monitoring; nutritional support vital. Growth hormone considered.
  • Living donor kidney transplant often preferred for better outcomes.

⭐ PTLD (Post-Transplant Lymphoproliferative Disorder), often EBV-related, is a significant concern in pediatric solid organ transplant, with incidence varying by organ and immunosuppression intensity.

Transplantation in Special Populations - Golden Years, New Leases

  • Eligibility: Chronological age (e.g., >65 yrs) less critical than physiological age & comorbidities.
  • Key Challenges:
    • ↑ Comorbidities (cardiac, diabetes, prior malignancy).
    • Immunosenescence: may ↓ rejection but ↑ infection/malignancy risk.
    • Polypharmacy & frailty assessment crucial.
  • Evaluation: Comprehensive Geriatric Assessment (CGA) vital.
  • Immunosuppression: Tailored regimens to balance efficacy against infection risk.
  • Donor Considerations: Often utilize Expanded Criteria Donors (ECD).
  • Outcomes: Good quality of life achievable; higher risk of infection, cardiovascular events.

⭐ Despite immunosenescence potentially reducing acute rejection, elderly transplant recipients face increased mortality from infections and cardiovascular events.

Geriatric patient discusses transplant options

Transplantation in Special Populations - Viral Hurdles, Hopeful Horizons

  • HIV+ Recipients:
    • Criteria: CD4 >200 cells/µL (some protocols >100), undetectable viral load (<50 copies/mL) for ≥6 months.
    • HAART essential; watch for drug interactions (CNIs, mTOR inhibitors).
  • HIV+ Donors (e.g., HOPE Act principles):
    • Permitted for HIV+ recipients under specific research protocols and consent.
  • Hepatitis B (HBV):
    • Recipients: Lifelong antiviral prophylaxis (e.g., Entecavir/Tenofovir) ± HBIG post-transplant.
    • HBcAb+ (core antibody positive) donors: Risk of de novo HBV in recipient; recipient requires prophylaxis.
  • Hepatitis C (HCV):
    • Recipients: Direct-Acting Antivirals (DAAs) achieve Sustained Virologic Response (SVR) >95%. Treat pre or post-transplant. Untreated risks fibrosing cholestatic hepatitis.
    • HCV NAT+ donors: Increasingly used for HCV+ recipients; also for HCV- if DAAs are assured post-transplant.

⭐ HIV+ patients on stable HAART with an undetectable viral load and adequate CD4 count (typically >200 cells/µL) have post-transplant outcomes comparable to HIV-negative recipients.

HCV-viremic kidney transplant outcomes

Transplantation in Special Populations - Fertile Futures, Careful Crafting

  • Pregnancy Post-Transplant:
    • High-risk; requires multidisciplinary care.
    • Optimal: 1-2 years post-transplant, stable graft, maintenance immunosuppression.
  • Immunosuppression (Pregnancy):
    • AVOID: Mycophenolate (MMF/MPA) 📌 MMF = My Fetus Fails. Switch to Azathioprine (AZA) ≥6 weeks pre-conception.
    • USE: Tacrolimus (preferred CNI), low-dose Prednisolone.
    • CONTRAINDICATED: Sirolimus, Everolimus.
  • Risks:
    • Maternal: Pre-eclampsia, gestational diabetes, infection, rejection.
    • Fetal: Prematurity, IUGR.
  • Male Fertility: CNIs generally safe; Sirolimus/MMF may impair.
  • Breastfeeding: Generally not advised; specialist consultation.

⭐ Mycophenolate (MMF/MPA) is highly teratogenic; switch to Azathioprine ≥6 weeks before conception.

High‑Yield Points - ⚡ Biggest Takeaways

  • Pregnancy post-transplant is possible; avoid Mycophenolate Mofetil (MMF) and Sirolimus.
  • Elderly recipients face ↑ infection and ↑ malignancy risks; cardiac fitness is crucial.
  • Pediatric transplants risk growth issues and PTLD; non-adherence is a concern.
  • HIV+ patients can be transplanted with undetectable viral load and good CD4 counts.
  • HCV+ recipients can receive HCV+ organs; DAAs improve outcomes significantly.
  • ABO-incompatible & highly sensitized patients: Transplant possible with desensitization protocols (e.g., IVIG, Rituximab).

Practice Questions: Transplantation in Special Populations

Test your understanding with these related questions

HLA typing is useful in:

1 of 5

Flashcards: Transplantation in Special Populations

1/8

Which kidney is taken during donor transplantation? Why? _____

TAP TO REVEAL ANSWER

Which kidney is taken during donor transplantation? Why? _____

Left

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial